{"id":9350,"date":"2026-01-06T14:35:16","date_gmt":"2026-01-06T06:35:16","guid":{"rendered":"https:\/\/regask.com\/?p=9350"},"modified":"2026-01-06T14:35:16","modified_gmt":"2026-01-06T06:35:16","slug":"la-ema-actualiza-la-guia-sobre-los-protocolos-de-gestion-de-cambios-posteriores-a-la-aprobacion-para-fortalecer-el-cumplimiento-del-ciclo-de-vida-de-los-medicamentos","status":"publish","type":"post","link":"https:\/\/regask.com\/es\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\/","title":{"rendered":"La EMA actualiza la gu\u00eda sobre la gesti\u00f3n de cambios posteriores a la aprobaci\u00f3n\u2026"},"content":{"rendered":"<p>En <strong>11 de diciembre de 2025,<\/strong> el <a href=\"https:\/\/www.ema.europa.eu\/en\/homepage\"><strong>Agencia Europea de Medicamentos (EMA)<\/strong><\/a> publicado <strong>Orientaci\u00f3n revisada sobre los Protocolos de Gesti\u00f3n de Cambios Posteriores a la Aprobaci\u00f3n (PACMP),<\/strong> Actualizaci\u00f3n del marco para la gesti\u00f3n del ciclo de vida de los medicamentos de uso humano en toda la Uni\u00f3n Europea. La gu\u00eda incorpora la experiencia regulatoria adquirida desde 2012 y se alinea con la <strong>Reglamento y directrices actualizados sobre variaciones de la UE,<\/strong> que surten efecto en <strong>15 de enero de 2026.<\/strong> Se aplica a todos los productos medicinales humanos y se centra en permitir un manejo regulatorio m\u00e1s r\u00e1pido y predecible de los cambios de calidad calificadores.<\/p>\n<div class=\"row\"  id=\"row-591187779\">\n\n\t<div id=\"col-789408605\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"gap-1246730911\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1246730911 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h2>Explicaci\u00f3n de la directriz actualizada<\/h2>\n\t<div id=\"gap-1498773177\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1498773177 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>La gu\u00eda revisada aclara que <strong>Los PACMP pueden presentarse<\/strong> como parte de una iniciativa <strong><a href=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\">autorizaci\u00f3n de comercializaci\u00f3n<\/a> solicitud (MAA),<\/strong> como un <strong>extensi\u00f3n de l\u00ednea,<\/strong> o a trav\u00e9s de una <strong>Variaci\u00f3n de tipo II<\/strong>, lo que permite a las empresas predefinir estrategias para futuros cambios de calidad. Explica que los cambios implementados bajo un PACMP aprobado generalmente se procesan utilizando <strong>tipos de variaci\u00f3n de menor riesgo, como el tipo IA, IAIN o IB,<\/strong> en lugar de procedimientos m\u00e1s complejos utilizados en las v\u00edas de variaci\u00f3n est\u00e1ndar.<\/p>\n<p>La gu\u00eda tambi\u00e9n confirma que <strong>Se permiten PACMP de usos m\u00faltiples,<\/strong> siempre que las condiciones predefinidas y los criterios de aceptaci\u00f3n se mantengan inalterados a lo largo del tiempo. Sin embargo, establece claramente que <strong>Los PACMP no se pueden utilizar<\/strong> para cambios que requieren intervenci\u00f3n cl\u00ednica o no cl\u00ednica <strong>evaluaci\u00f3n de datos<\/strong> o por cambios que en s\u00ed mismos resultan<strong> en una l\u00ednea de extensi\u00f3n.\u00a0<\/strong><\/p>\n<p>Para apoyar la transparencia y la supervisi\u00f3n del ciclo de vida, la EMA exige que <strong>Todos los PACMP se enumerar\u00e1n en el M\u00f3dulo 3.2.R del expediente,<\/strong> garantizar una documentaci\u00f3n clara de las estrategias de cambio aprobadas. Adem\u00e1s, la versi\u00f3n revisada <strong>Las directrices de variaci\u00f3n de la UE se aplican \u00fanicamente a las variaciones de implementaci\u00f3n presentadas a partir del 15 de enero de 2026.,<\/strong> establecer un cronograma de transici\u00f3n claro para los equipos reguladores.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-789408605 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1313680658\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Fecha l\u00edmite para comentarios<\/h2>\n\t<div id=\"gap-726430227\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-726430227 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><strong>No se ha especificado ninguna fecha l\u00edmite para comentarios o consultas<\/strong> para esta actualizaci\u00f3n de orientaci\u00f3n.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1313680658 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1465492435\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Por qu\u00e9 es importante<\/h2>\n\t<div id=\"gap-1768609492\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1768609492 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Esta actualizaci\u00f3n proporciona mayor <strong>claridad regulatoria<\/strong> En torno al uso de los PACMP, apoya <strong>alineaci\u00f3n digital<\/strong> con marcos de variaci\u00f3n de la UE actualizados y mejora <strong>eficiencia<\/strong> Al permitir que los cambios de calidad de menor riesgo sigan v\u00edas predecibles, la gu\u00eda mantiene el rigor regulatorio y minimiza la carga administrativa innecesaria durante la gesti\u00f3n del ciclo de vida del producto.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1465492435 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-532154582\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Para qui\u00e9n es relevante esta actualizaci\u00f3n<\/h2>\n\t<div id=\"gap-552775222\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-552775222 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Su orientaci\u00f3n es relevante para <strong>Asuntos Regulatorios, Garant\u00eda de Calidad, CMC,<\/strong> y <strong>Operaciones Regulatorias<\/strong> equipos responsables de gestionar los cambios posteriores a la aprobaci\u00f3n, el mantenimiento de los expedientes y la planificaci\u00f3n del ciclo de vida de los medicamentos humanos dentro de la UE.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-532154582 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-975025705\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Pr\u00f3ximos pasos<\/h2>\n\t<div id=\"gap-1228492101\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1228492101 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Las organizaciones deben revisar los sistemas existentes y planificados. <strong>PACMP<\/strong> para confirmar la alineaci\u00f3n con la gu\u00eda revisada de la EMA y la actualizaci\u00f3n <strong>Reglamento de variaciones de la UE.<\/strong> Los equipos reguladores deben garantizar que las listas del PACMP se mantengan con precisi\u00f3n <strong>M\u00f3dulo 3.2.R<\/strong> y coordinar entre funciones para prepararse para la implementaci\u00f3n de las variaciones presentadas desde <strong>15 de enero de 2026<\/strong> adelante.<\/p>\n<p>A medida que los equipos reguladores eval\u00faan la elegibilidad del PACMP, las v\u00edas de variaci\u00f3n y la preparaci\u00f3n del expediente seg\u00fan el marco revisado, <a href=\"https:\/\/regask.com\/es\/\">RegASK<\/a> Puede apoyar la monitorizaci\u00f3n continua y la implementaci\u00f3n estructurada.<\/p>\n<p><strong><a href=\"https:\/\/regask.com\/es\/\">RegASK<\/a> es una plataforma l\u00edder de inteligencia regulatoria y orquestaci\u00f3n de flujos de trabajo con inteligencia artificial de agencia.<\/strong> que permite a las organizaciones globales en sectores altamente regulados, como productos de consumo y ciencias de la vida, navegar proactivamente en entornos regulatorios complejos. Al combinar tecnolog\u00eda avanzada <strong>IA agente<\/strong> con expertos en el sector, <a href=\"https:\/\/regask.com\/es\/\">RegASK<\/a> Proporciona informaci\u00f3n predictiva y procesable oportuna y automatizaci\u00f3n de extremo a extremo, agilizando los procesos de cumplimiento, mitigando riesgos y acelerando el acceso al mercado en m\u00e1s de 157 pa\u00edses. <a href=\"https:\/\/regask.com\/es\/producto\/\">M\u00e1s informaci\u00f3n<\/a> o <a href=\"https:\/\/regask.com\/es\/reservar-una-demostracion\/\">Reserve una demostraci\u00f3n ahora.\u00a0<\/a><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-975025705 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-1888739450\">\n\n\t<div id=\"col-2094046890\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>Preguntas frecuentes<\/h3>\n\t<div id=\"gap-924201150\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-924201150 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h4>\u00bfQu\u00e9 es un Protocolo de Gesti\u00f3n de Cambios Posterior a la Aprobaci\u00f3n (PACMP)?<\/h4>\n\t<div id=\"gap-1346043773\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1346043773 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>A <strong>PACMP<\/strong> es una estrategia regulatoria estructurada y previamente aprobada que define c\u00f3mo se pueden implementar cambios espec\u00edficos de calidad en un producto medicinal durante su ciclo de vida utilizando condiciones y criterios de aceptaci\u00f3n acordados.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-2094046890 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-49804924\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>\u00bfCu\u00e1ndo entra en vigor la gu\u00eda revisada del PACMP de la EMA?<\/h4>\n\t<div id=\"gap-2083298332\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2083298332 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>La gu\u00eda revisada se aplica en consonancia con la <strong>Reglamento y directrices sobre variaciones de la UE vigentes a partir del 15 de enero de 2026<\/strong>, para implementar las variaciones presentadas a partir de esa fecha.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-49804924 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1355889979\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>\u00bfQu\u00e9 cambios est\u00e1n excluidos de los PACMP seg\u00fan la gu\u00eda actualizada?<\/h4>\n\t<div id=\"gap-162626533\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-162626533 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>PACMP <strong>No se puede utilizar para cambios que requieran evaluaci\u00f3n de datos cl\u00ednicos o no cl\u00ednicos.<\/strong> o para cambios que resulten en una <strong>l\u00ednea de extensi\u00f3n.\u00a0<\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1355889979 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1593164518\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>\u00bfC\u00f3mo puede RegASK ayudar a los equipos a gestionar las actualizaciones regulatorias relacionadas con PACMP?<\/h4>\n\t<div id=\"gap-671513528\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-671513528 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><a href=\"https:\/\/regask.com\/es\/\">RegASK<\/a> ayuda a los equipos regulatorios y de calidad a rastrear las actualizaciones de las pautas de la EMA, evaluar la elegibilidad del PACMP y alinear los flujos de trabajo de expedientes y variaciones a trav\u00e9s de inteligencia regulatoria impulsada por IA y procesos de cumplimiento automatizados.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1593164518 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>","protected":false},"excerpt":{"rendered":"<p>On 11 December 2025, the European Medicines Agency (EMA) published revised guidance on Post-Approval Change Management Protocols (PACMPs), updating the framework for lifecycle management of human medicinal products across the European Union. The guidance incorporates regulatory experience gained since 2012 and aligns with the updated EU Variations Regulation and Guidelines, which take effect on 15&#8230;<\/p>","protected":false},"author":41,"featured_media":9367,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[529,33,35],"tags":[],"class_list":["post-9350","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-europe","category-news","category-pharma-biotech-latest-insights"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.3 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>EMA Updates Guidance on Post-Approval Change Management<\/title>\n<meta name=\"description\" content=\"Explore the EMA updates on Post-Approval Change Management Protocols to enhance compliance in medicinal product lifecycles.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/es\/la-ema-actualiza-la-guia-sobre-los-protocolos-de-gestion-de-cambios-posteriores-a-la-aprobacion-para-fortalecer-el-cumplimiento-del-ciclo-de-vida-de-los-medicamentos\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EMA Updates Guidance on Post-Approval Change Management Protocols to Strengthen Medicinal Product Lifecycle Compliance\" \/>\n<meta property=\"og:description\" content=\"Explore the EMA updates on Post-Approval Change Management Protocols to enhance compliance in medicinal product lifecycles.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/es\/la-ema-actualiza-la-guia-sobre-los-protocolos-de-gestion-de-cambios-posteriores-a-la-aprobacion-para-fortalecer-el-cumplimiento-del-ciclo-de-vida-de-los-medicamentos\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-06T06:35:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2025\/12\/ema-updates-guidance-post-approval-change-management-protocols-strengthen-medicinal-product-lifecycle-compliance.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Shaffa Renaningtyas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Shaffa Renaningtyas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\\\/\"},\"author\":{\"name\":\"Shaffa Renaningtyas\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/b0e1938ef6f244f9f052a21f21cba1b6\"},\"headline\":\"EMA Updates Guidance on Post-Approval Change Management&hellip;\",\"datePublished\":\"2026-01-06T06:35:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\\\/\"},\"wordCount\":826,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/ema-updates-guidance-post-approval-change-management-protocols-strengthen-medicinal-product-lifecycle-compliance.png\",\"articleSection\":[\"Europe &amp; Central Asia\",\"Regulatory News\",\"Pharma and Biotech\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\\\/\",\"name\":\"EMA Updates Guidance on Post-Approval Change Management\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/ema-updates-guidance-post-approval-change-management-protocols-strengthen-medicinal-product-lifecycle-compliance.png\",\"datePublished\":\"2026-01-06T06:35:16+00:00\",\"description\":\"Explore the EMA updates on Post-Approval Change Management Protocols to enhance compliance in medicinal product lifecycles.\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/ema-updates-guidance-post-approval-change-management-protocols-strengthen-medicinal-product-lifecycle-compliance.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/ema-updates-guidance-post-approval-change-management-protocols-strengthen-medicinal-product-lifecycle-compliance.png\",\"width\":800,\"height\":600,\"caption\":\"Ema Updates Guidance Post Approval Change Management Protocols Strengthen Medicinal Product Lifecycle Compliance\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"Empowering Smarter Regulatory Decisions\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/playlist?list=PL6yPC6gFqelkHbOeyUVKjtHOZXZ2LQbJd\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/b0e1938ef6f244f9f052a21f21cba1b6\",\"name\":\"Shaffa Renaningtyas\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"La EMA actualiza la gu\u00eda sobre la gesti\u00f3n de cambios posteriores a la aprobaci\u00f3n","description":"Explore las actualizaciones de la EMA sobre los protocolos de gesti\u00f3n de cambios posteriores a la aprobaci\u00f3n para mejorar el cumplimiento en los ciclos de vida de los medicamentos.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/es\/la-ema-actualiza-la-guia-sobre-los-protocolos-de-gestion-de-cambios-posteriores-a-la-aprobacion-para-fortalecer-el-cumplimiento-del-ciclo-de-vida-de-los-medicamentos\/","og_locale":"es_ES","og_type":"article","og_title":"EMA Updates Guidance on Post-Approval Change Management Protocols to Strengthen Medicinal Product Lifecycle Compliance","og_description":"Explore the EMA updates on Post-Approval Change Management Protocols to enhance compliance in medicinal product lifecycles.","og_url":"https:\/\/regask.com\/es\/la-ema-actualiza-la-guia-sobre-los-protocolos-de-gestion-de-cambios-posteriores-a-la-aprobacion-para-fortalecer-el-cumplimiento-del-ciclo-de-vida-de-los-medicamentos\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-01-06T06:35:16+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/12\/ema-updates-guidance-post-approval-change-management-protocols-strengthen-medicinal-product-lifecycle-compliance.png","type":"image\/png"}],"author":"Shaffa Renaningtyas","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Shaffa Renaningtyas","Est. reading time":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\/#article","isPartOf":{"@id":"https:\/\/regask.com\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\/"},"author":{"name":"Shaffa Renaningtyas","@id":"https:\/\/regask.com\/#\/schema\/person\/b0e1938ef6f244f9f052a21f21cba1b6"},"headline":"EMA Updates Guidance on Post-Approval Change Management&hellip;","datePublished":"2026-01-06T06:35:16+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\/"},"wordCount":826,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/12\/ema-updates-guidance-post-approval-change-management-protocols-strengthen-medicinal-product-lifecycle-compliance.png","articleSection":["Europe &amp; Central Asia","Regulatory News","Pharma and Biotech"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/regask.com\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\/","url":"https:\/\/regask.com\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\/","name":"La EMA actualiza la gu\u00eda sobre la gesti\u00f3n de cambios posteriores a la aprobaci\u00f3n","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/12\/ema-updates-guidance-post-approval-change-management-protocols-strengthen-medicinal-product-lifecycle-compliance.png","datePublished":"2026-01-06T06:35:16+00:00","description":"Explore las actualizaciones de la EMA sobre los protocolos de gesti\u00f3n de cambios posteriores a la aprobaci\u00f3n para mejorar el cumplimiento en los ciclos de vida de los medicamentos.","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/ema-updates-guidance-on-post-approval-change-management-protocols-to-strengthen-medicinal-product-lifecycle-compliance\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/12\/ema-updates-guidance-post-approval-change-management-protocols-strengthen-medicinal-product-lifecycle-compliance.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/12\/ema-updates-guidance-post-approval-change-management-protocols-strengthen-medicinal-product-lifecycle-compliance.png","width":800,"height":600,"caption":"Ema Updates Guidance Post Approval Change Management Protocols Strengthen Medicinal Product Lifecycle Compliance"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Habilitando decisiones regulatorias m\u00e1s inteligentes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/playlist?list=PL6yPC6gFqelkHbOeyUVKjtHOZXZ2LQbJd"]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/b0e1938ef6f244f9f052a21f21cba1b6","name":"Shaffa Renaningtyas"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/9350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/users\/41"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/comments?post=9350"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/9350\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media\/9367"}],"wp:attachment":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media?parent=9350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/categories?post=9350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/tags?post=9350"}],"curies":[{"name":"Gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}